Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
ImmunityBio, Inc.
OncoHost Ltd.
British Columbia Cancer Agency
Theratechnologies
Salubris Biotherapeutics Inc